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In patients with sick sinus syndrome (SSS), it is known that the use of atrial-based
pacing does not improve survival or reduce congestive heart failure (CHF) or
cardiovascular death compared with ventricular pacing, although atrial-based
pacing reduces the incidence of atrial fibrillation (AF) and may modestly reduce
stroke.1,2 However, the optimal pacing mode with either AAI(R) or DDD(R) is
still not clear in sinus-node dysfunction (SND) and intact atrioventricular (AV)
conduction, while the preservation of normal intraventricular conduction without
ventricular pacing in SND is thought to impart better ventricular function. 
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Purpose: The optimal pacing mode with either single chamber atrial pacemaker
(AAI or AAIR) or dual chamber pacemaker (DDD or DDDR) is still not clear in
sinus-node dysfunction (SND) and intact atrioventricular (AV) conduction.
Materials and Methods: Patients who were implanted with permanent pacemaker
using AAI(R) (n = 73) or DDD(R) (n = 113) were compared. Results: The baseline
characteristics were comparable between the two groups, with a mean follow-up
duration of 69 months. The incidence of death did not show statistical difference.
However, the incidence of hospitalization for congestive heart failure (CHF) was
significantly lower in the AAI(R) group (0%) than the DDD(R) group (8.8%, p =
0.03). Also, atrial fibrillation (AF) was found in 2.8% in the AAI(R) group, which
was statistically different from 15.2% of patients in the DDD(R) group (p = 0.01).
Four patients (5.5%) with AAI(R) developed AV block, and subsequently switched
to DDD(R) pacing. The risk of AF was lower in the patients implanted with AAI(R)
than those with DDD(R) [hazard ratio (HR), 0.84; 95% confidence interval, 0.72 to
0.97, p = 0.02]. Conclusion: In patients with SND and intact AV conduction,
AAI(R) pacing can achieve a better clinical outcome in terms of occurrence of CHF
and AF than DDD(R) pacing. These findings support AAI(R) pacing as the pre-
ferred pacing mode in patients with SND and intact AV conduction. 
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INTRODUCTION
The primary aim of the present study is to evaluate
which mode between AAI(R) and DDD(R) works better in
patients with SND and intact AV conduction.
This study is a retrospective, non-randomized trial analyz-
ing 986 patients who underwent pacemaker implantation
in Severance Cardiovascular Hospital, Yonsei University
Severance Hospital in South Korea, from January 1990 to
May 2004. Of these, 186 SND patients, aged equal or older
than 20 years, with normal AV conduction were included.
Of these patients, 73 (39%) patients were implanted with
AAI(R) and 113 (61%) patients were implanted with
DDD(R). A normal AV conduction was arbitrarily defined
as PQ interval ≤ 220 ms for patients ≤ 70 years and PQ
interval ≤ 260 ms for patients > 70 years, as used in a prior
study.3 
Evaluation of patients for medical history, physical exa-
mination, and echocardiography were done before pace-
maker implantation. Patients were followed up at 1 month,
3 months, and then once every 6 months. The follow-up
visits included physical examination, electrocardiogram
(ECG) recordings, pacemaker check-up, and recording of
outcome events. Patients were given a diary in which the
details of any medical contacts between their follow-up
visits were to be recorded. If the visit was missed, outcome
data were sought through a review of clinical records or
contact with patient’s family by nurses. 
The primary end points were death from cardiac or other
causes. Secondary end points included the composite of
death from other causes, hospitalization for stroke or CHF,
and AF. AF was detected by a standard 12 lead ECG ob-
tained at scheduled follow-up visits, and also by 24 hours
Holter ECG monitoring in patients with symptoms. Episo-
des of AF between the follow up visits were not recorded.
Pacemaker telemetry data were not collected because the
present study was the long-term follow-up results of AAI(R)
or DDD(R), and most of pacemakers had no ability to
report pacemaker telemetry data at the time of pacemaker
implantation. Patients were excluded if they underwent
cardiac surgery or AV node ablation, had multisite atrial or
ventricular pacing, or had bundle branch block or AF. Also,
patients with pacemaker with AF suppression pacing
algorithm were excluded from this study.
All analyses were performed using the SAS statistical
package version 9.1.3 (SAS, Inc, Cary, NC, USA). Conti-
nuous data were compared using unpaired Student’s t test
or Wilcoxon’s rank-sum test between different categories.
Treatment groups were compared by the Chi-square test for
discrete variables. Cumulative event rates were calculated
by the Kaplan-Meier methods, and differences between the
treatments groups were assessed with the log-rank test. In
addition, a Cox proportional hazard analysis was performed
for cumulative events at follow-up, with the results expressed
as hazard ratios [hazard ratio (HR); 90% confidential inter-
val (CI)]. For all tests, a 2-tailed p < 0.05 was considered
significant. Patients lost to follow-up were considered at
risk until the date of final contact, when they were censored. 
The average follow-up was 69.6 ± 49.7 months (upto 180
months) without significant difference between the two
groups (69.3 ± 56.8 months in the AAI(R) group  vs. 69.7
± 45.0 months in the DDD(R) group, p = 0.60). The mean
age was 58 years. Clinical follow-up was complete in 170
patients (91.4%) at the end of the study. The baseline cha-
racteristics of the patients, which were included in the
analyses were comparable (Table 1). 
Table 2 summarizes the result of the clinical events
between the two groups. The incidence of total death did
not show statistical difference (2.8% in the AAI(R) group
versus 7.1% in the DDD(R) group, p = 0.12), and the rate
of cardiovascular death was 1.4% in the AAI(R) group
compared with 2.7% in the DDD(R) group (p = 0.46).
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MATERIALS AND METHODS
Table 1. Baseline Characteristics of the Study Patients
AAI(R) (n = 73) DDD(R) (n = 113) p value
Female, n (%) 45 (61%) 55 (49%) 0.10
Age, yrs 58.9 ± 13.6 57.2 ± 15.7 0.45
Hypertension, n (%) 23 (31.5%) 34 (30.1%) 0.87
Diabetes, n (%) 8 (11.0%) 12 (10.6%) 1.0 
CAD, n (%) 4 (5.5%) 10 (8.8%) 0.57
CKD, n (%) 0 3 (2.7%) 0.28
LVEF (%) 63.7 ± 10.1 59.8 ± 12.0 0.22
CAD, coronary artery disease; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction.
Values in parensthesis are presented as percentage.
RESULTS
However, there was a higher proportion of DDD(R) mode
pacing with total and cardiovascular deaths in trend. Kaplan-
Meier curve depicting the event-free survival from any
death was not different significantly in the both groups (p
= 0.25 by log-rank test) (Table 2, Fig.1). 
Unadjusted analyses did not find any significant differ-
ence between the two groups in the rate of stroke. However,
the incidence of hospitalization for CHF was significantly
lower in the AAI(R) group (0%) than the DDD(R) group
(8.8%, p = 0.03) (Table 2, Fig. 2). Also, there was a predo-
minance of AF after pacemaker implantation in the DDD(R)
group (2.8 % in the AAI(R) group vs. 15.2% in the DDD(R)
group, p = 0.01) (Table 2, Fig. 3). The secondary end points,
the composite of death from other causes, hospitalization
for stroke or CHF, and AF, occurred in 60 patients. There
was a significant difference between AAI(R) and DDD(R)
in the incidence of secondary end point (17.8% in the AAI
(R) group versus 41.6% in the DDD(R) group, p = 0.02).
During the follow-up period,the pacing mode was swit-
ched to dual-chamber pacing in four patients (5.5%) with
AAI(R). Three patients required change of pacing mode
due to second or higher degree AV block. The symptoms
associated with AV block were dizzy spells and syncope.
One patient required insertion of a ventricular lead because
of a prolonged PR interval. Other patients received dual-
chamber pacemakers at the time of pacemaker implantation.
Therefore, they had their pacing mode changed to DDD(R)
without insertion of the ventricular lead.
Cox multivariate analysis was performed to evaluate the
independent predictors of incidence of CHF, AF, and
secondary end points (Table 3). Independent predictors
were determined for each end point in the both groups by
using all univariate significant (p < 0.1) baseline character-
istics. Age proved to be predictor of development of CHF
(HR; 1.07, 95% CI; 1.02-1.12). The risk of occurrence of
AF was lower in the AAI(R) group than DDD(R) group
(HR; 0.84, 95% CI; 0.72-0.97). AAI(R) had a protective
effect in secondary events (HR; 0.89, 95% CI; 0.84-0.96).
Table 4 summarizes the result of the clinical events by
cumulative percent ventricular paced (Cum%VP). Cum%-
VP was determined from stored pacemaker diagnostic data
at each follow-up visit. As seen in the table, the incidence
of AF was significantly higher in the patients with Cum%-
VP, ranging from 90% pacing to 100%. However, there
was no statistical difference between the patients with low
Cum%VP and high Cum%VP in the incidence of total
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Table 2. Clinical Events and End Points of the Study Patients 
AAI(R) (n = 73) DDD(R) (n = 113) p value
Primary end point
Total death (n, %) 2 (2.8%) 8 (7.1%) 0.12
Cardiac death (n, %) 1 (1.4%) 3 (2.7 %) 0.46
Secondary end point
Stroke (n, %) 1 (1.4%) 6 (5.3%) 0.16
CHF (n, %) 0 9 (8.8%) 0.03
AF (n, %) 2 (2.8%) 18 (15.2%) 0.01
CHF, congestive heart failure; AF, atrial fibrillation.
Values are presented as n (%) or mean ± SD. 
Pr
op
or
tio
ns
 e
ve
nt
 fr
ee
0 2 4 6 8 10
Time (year)
  73 47 43 37 29 23
113
AAI(R)
DDD(R)
AAI(R) group
DDD(R) group
93 72 50 34 22
0.6
0.8
1.0
Fig. 1. Kaplan-Meier event-free survival from total death, primary end point. The
cumulative incidence of total death was not significant in both groups (p = 0.25
by log-rank test). There was no significant difference, but a higher incidence of
events in the DDD(R) group than in the AAI(R) group.
Pr
op
or
tio
ns
 e
ve
nt
 fr
ee
0 2 4 6 8 10
Time (year)
73 47 43 37 29 23
113
AAI(R)
DDD(R)
AAI(R) group
DDD(R) group
90 70 49 34 22
0.6
0.8
1.0
Fig. 2. Kaplan-Meier event-free survival from hospitalization for CHF. The
cumulative incidence of hospitalization for CHF was significantly lower in the
AAI(R) group than the DDD(R) group (p = 0.02 by log-rank test). CHF, congestive
heart failure.
death, stroke, and CHF.
There were 4 complications among 186 patients (2.15%).
The most frequent complications were dislodgement of
atrial lead in the AAI(R) group (3 cases). One case of lead
infection developed in the DDD(R) group. All patients
successfully underwent reoperation. There were no instan-
ces of death as a complication of implantation of a perma-
nent pacemaker. 
This study is a retrospective, non-randomized trial compar-
ing AAI(R) mode to  DDD(R) mode in patients with SND
and normal AV conduction without AF. The main findings
of the present analysis of 186 patients presenting with
SND and normal AV conduction without AF are 1) no
significant differences in primary end point, defined as death
from cardiac or other causes between the two groups, and
2) the beneficial effect of atrial pacing with regard to the
reduction of the occurrence of AF and CHF. The incidence
of secondary end point was significantly higher, and there
was a trend towards increased cardiac and total death in the
DDD(R) group. These findings are in accordance with the
previous studies by Nielsen, et al.4 and by Masumoto, et al.5
which reported a lower incidence of AF and CHF in patients
with atrial pacing. 
Documented advantages of single lead atrial pacing in
SND and normal AV conduction include lower mortality,
lower rate of thromboembolism, and less frequent develop-
ment of AF.6,7 However, the disadvantage of this pacing
modality is the development of an AV block. Both pacing
modes preserve AV synchrony, however, if AV block oc-
curs, this event may require implantation of an additional
ventricular lead in order to switch to dual chamber pacing.
Upgrading to a dual-chamber pacing system often results
in higher morbidity than a de novo dual-chamber implan-
tation.8 In this study, the incidence of AV block was slightly
higher than that reported in the past literature (4/110, 0.6%
per year).3 The result that three patients with AAI(R) de-
veloped symptomatic second or high degree AV block sug-
gests that the development of AV block must be consider-
ed, when evaluating the advantages of AAI(R) mode in
Intact Atrioventricular Node Conduction
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DISCUSSION
Table 3. Multivariate Cox Predictors for Secondary Events
Predictor
Multivariate Cox Predictors
HR 95% CI p value
CHF Age 1.07 1.02 - 1.12 0.01
Mode 0.27 0.0 - 1.5 0.96
AF Age 1.01 0.98 - 1.04 0.61
Mode 0.84 0.72 - 0.97 0.02
Secondary end point Age 1.04 1.02 - 1.06 0.001
Mode 0.89 0.84 - 0.96 0.001
HR, hazard ratio; CHF, congestive heart failure; AF, atrial fibrillation.
Table 4. Rates of Death, Stroke, CHF and AF by Cumulative Percent Ventricular Paced (Cum%VP) in the DDD(R) 
Group
Cum%VP Death (%) Stroke (%) CHF (%) AF (%)
< 10% 5 (62.5) 2 (33.3) 3 (33.3) 3 (16.7)
≥ 10 - 50% 0 (0) 1 (16.7) 1 (11.1) 2 (11.1)
> 50 - 90% 0 (0) 0 (0) 1 (11.1) 3 (16.7)
> 90% 3 (37.5) 3 (50.0) 4 (44.4) 10 (55.6)
Total 8 (7.1) 6 (5.3) 9 (8.8) 18 (15.2)
CHF, congestive heart failure; AF, atrial fibrillation; Cum%VP, cumulative percent ventricular paced.
Values are presented as n (%) or mean ± SD.
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Fig. 3. Kaplan-Meier event-free survival from hospitalization for AF. The curve
was significantly better in the AAI(R) group than in the DDD(R) group (p = 0.01 by
log-rank test). AF, atrial fibrillation.
patients with SND without AF. But, it should be noted that
most AV conduction disturbances may be due to antiarrhy-
thmic agent rather than degeneration of the conduction
system.5 It remains controversial whether Wenckebach
block point is predictive of high degree AV block. One of
our patients had the pacing mode switched from AAI(R) to
DDD(R) because of an early Wenkebach block point. The
presence of a bundle-branch block on the electrocardio-
gram at implantation is a good predictor of subsequent AV
block.9
In the present study, we demonstrated that AAI(R)
pacing mode had a preventive effect on the development
of AF than DDD(R) mode. A previous report showed that
dual-chamber pacing may also prevent the progression to
AF by overdriving the atria, which is somewhat effective
in suppressing atrial ectopic activity and AF.10 However,
Nielsen, et al. showed that a long-term dual-chamber
pacing induces left atrial dilation by right ventricular (RV)
pacing, subsequently promoting AF, and  Kristensen, et al.
demonstrated that single atrial chamber pacing was asso-
ciated with significantly less AF in patients with SSS and
normal AV conduction.11 Left atrial (LA) dilation resulting
from long-term dual-chamber pacing induces AF. The
significant reduction of CHF in the AAI(R) group is in
accordance with previous studies.12-14 It is likely that the LA
dilation and mechanical contraction pattern of the ventricles
induced by RV pacing are associated with a decrease in the
LV systolic and diastolic function and an increase in the
right atrial pressure and the pulmonary capillary wedge
pressure.4 A previous study reported that it is associated
with increased number of CHF hospitalizations when vent-
ricular pacing occurs more than 40% of the time.7 MOST
investigators showed  that V-V dyssynchrony may neutral-
ize the benefits of AV synchrony in patients with intact
AV node conduction. In their results, Cum%VP was an
independent predictors of CHF hospitalization.15 In patients
with preserved LV systolic function on permanent RV api-
cal pacing, RV apical pacing is associated with mechanical
LV dyssynchrony.16 It is well known that RV pacing causes
chronic changes in regional myocardial perfusion, cellular
structure, and ventricular geometry that eventually may
impair ventricular performance.17-19
In out results, the DDD(R) group with Cum%VP > 90%
had a greater incidence of AF than those with Cum%VP <
90%. Based on the present result, it is quite clear that
single atrial chamber pacing should be the choice for pati-
ents with LV dysfunction, risk of stroke and AF. 
In the present study, the incidence of stroke was less
with AAI pacing, but this was not statistically significant.
None of the large randomized trials has so far individually
found a reduction in stroke.20-22 In ‘MOST’ trials that were
designed to analyze predictors of stroke and CHF in patients
who were paced for SSS, only clinical characteristics such
as hypertension, and diabetes, but not the mode of pacing,
were associated with subsequent stroke.23 However, there
is a direct relationship between AF and stroke.15 Given the
observed individual and aggregate reduction in AF, a
reduction in stroke would seem to be plausible.20
Limitations in the design of the present study might have
affected our results. First, the limitation of this study was
relatively small number of enrolled patients. Second, the
study was non-randomized, with regard to implanted pace-
maker type and duration of medication. Third, we did not
take other complications, such as pacemaker syndrome,
quality of life, lead failure, and events related to venous
access, into consideration. 
Nevertheless, to our best knowledge, this is the largest
result reported in a single medical center with the longest
follow-up, showing AAI(R) as an effective mode for
patients with SND and intact AV conduction.
In conclusion, AAI(R) mode pacing appeared to achieve
a better clinical outcome in terms of occurrence of AF and
secondary end point than DDD(R) mode pacing in pati-
ents with SND and intact AV conduction. The incidence of
development of AV block during follow-up periods was
low in the AAI(R) group. However, enthusiasm for AAI(R)
mode is low because of the low but potentially unpredic-
table occurrence of AV block.3 More recently, in order to
combine the advantages of AAI(R) pacing and DDD(R)
pacing, managed ventricular pacing has been developed.
This provides true AAI(R) pacing, monitors AV conduc-
tion, and switches to DDD(R) pacing if intrinsic AV con-
duction fails. This may be the promising pacing mode of
choice in these patients.
In this small cohort study, these findings support AAI(R)
mode pacing as the preferred pacing mode in patients with
SND and intact AV conduction.
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